App-Quantinova.ai

Financial impact of tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer bearing METex14 skipping in the United States.

Matthew Stargardter - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Capmatinib

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.

Hyun Cheol Cheol Chung - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Pembrolizumab

Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.

Howland E. Crosswell - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Adcetris

Recurrence risk in early breast cancer as defined by clinicopathologic features.

Kristin M. Sheffield - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.

Paul M. Barr - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

chlorambucil

Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.

John Raymond Zalcberg - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastrointestinal stromal tumor

DCC-2618

Alessio Cortellini - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

Stephen R. D. Johnston - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Palbociclib

Preliminary results of molecular screening for FGFR alterations (alts) in the RAGNAR histology-agnostic study with the FGFR-inhibitor (FGFRi) erdafitinib.

Christophe Massard - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of the COVID-19 pandemic on treatment in patients (pts) with gynecological (GYN) cancer: A comparison with 2019 data from Guy’s Cancer Centre.

Vasiliki Michalarea - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Filgrastim

Integration of a polygenic risk score of kidney function with cumulative cisplatin dose and time variables for the prediction of serum platinum levels.

Megan Shuey - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

Cisplatin

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.

Victoria Atkinson - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Influenza

Dabrafenib Mesylate

Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.

Richard Adams - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine

Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).

Komal L. Jhaveri - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

LHRH

Mathematical predication models to optimize post-treatment surveillance in HPV-associated oropharyngeal cancer.

Vivek Nair - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Oropharyngeal carcinoma

N/A

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.

Jedd D. Wolchok - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Nivolumab

Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer.

Nima Sharifi - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Androgen Tear

A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.

Manish R. Patel - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Atezolizumab

Coverage of symptomatic toxicities from the common terminology criteria for adverse events (CTCAE) framework within the european organization for research and treatment of cancer (EORTC) item library.

Claire Piccinin - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.

Rajat Bannerji - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

Polatuzumab vedotin

Filters

45280 Abstracts